Analysts Set Indivior PLC (NASDAQ:INDV) Price Target at $22.00

Indivior PLC (NASDAQ:INDV) has earned an average rating of “Buy” from the eight research firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation, five have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $32.1667.

Several equities analysts have recently weighed in on the stock. HC Wainwright lifted their target price on shares of Indivior from $28.00 to $35.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Weiss Ratings reiterated a “hold (c)” rating on shares of Indivior in a research note on Friday, October 31st. Jefferies Financial Group assumed coverage on shares of Indivior in a research note on Tuesday, July 22nd. They issued a “buy” rating and a $20.00 target price for the company. Northland Securities set a $40.00 target price on shares of Indivior in a research note on Friday, October 31st. Finally, Craig Hallum reiterated a “buy” rating and issued a $41.00 target price on shares of Indivior in a research note on Friday, October 31st.

Indivior Stock Performance

NASDAQ INDV opened at $32.05 on Thursday. Indivior has a 52-week low of $7.62 and a 52-week high of $32.34. The company has a 50-day simple moving average of $24.69 and a 200 day simple moving average of $18.68. The company has a market capitalization of $4.42 billion, a PE ratio of 51.69 and a beta of 0.68.

Indivior (NASDAQ:INDV) last posted its earnings results on Thursday, October 30th. The company reported $0.72 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.34. The firm had revenue of $314.00 million during the quarter, compared to the consensus estimate of $257.66 million. Indivior had a net margin of 6.65% and a negative return on equity of 86.28%. Indivior has set its FY 2025 guidance at EPS. As a group, analysts forecast that Indivior will post 1.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Indivior

Hedge funds have recently bought and sold shares of the company. CWM LLC purchased a new position in Indivior during the third quarter valued at approximately $25,000. Raymond James Financial Inc. purchased a new position in Indivior during the second quarter valued at approximately $26,000. Plato Investment Management Ltd purchased a new position in Indivior during the third quarter valued at approximately $52,000. Blue Trust Inc. purchased a new position in Indivior during the third quarter valued at approximately $99,000. Finally, Amalgamated Bank purchased a new position in Indivior during the second quarter valued at approximately $61,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.